ABSTRACT
OBJECTIVE: To investigate the differences and correlation between blood inflammatory indexes such as monocytes (MONO), lymphocytes (LYM), haemoglobin (HGB), neutrophils (NEU), platelets (PLT), ultrasensitive C-reactive protein, albumin and platelet/lymphocyte ratio (PLR), NEU/LYM ratio (NLR), MONO/LYM ratio (MLR) and clinicopathologic characteristics of patients with non-small cell lung cancer (NSCLC). METHODS: 187 patients with NSCLC who were first diagnosed in 2017-2023 and 102 with healthy check-ups during the same period (control group) were retrospectively selected as study subjects to compare the differences in inflammatory indexes between the two groups and the levels of inflammatory indexes in NSCLC patients with different clinicopathologic characteristics. RESULTS: Correlation analysis between blood inflammatory indexes and clinicopathologic features in NSCLC group showed that C-reactive protein, CAR, and PLR values were different in different pathologic types (P<0.05). The values of NEU, MONO, C-reactive protein, MLR, NLR, CAR and albumin were different among various degrees of differentiation (P<0.05). There were differences in LYM, albumin, MLR, NLR, CAR, and C-reactive protein among M stage subgroups (P<0.05). Analysis of the efficacy of early diagnosis of non-small cell lung cancer has been shown, the AUC of NLR was 0.796, sensitivity of 0.679, specificity of 0.176, 95% CI=0.743-0.849 (P<0.001). The AUC of albumin was 0.977, the sensitivity was 0.941, the specificity was 0.941, and 95% CI was 0.959-0.994 (P<0.001). CONCLUSION: Blood inflammatory indexes are closely associated with NSCLC and vary according to pathologic features. Blood inflammatory indices can predict tumor pathologic staging and guide treatment for patients with NSCLC.
ABSTRACT
Objective: To explore the risk factors of recurrence within 1 year after radical resection of non-small cell lung cancer (NSCLC) and construct the nomogram model. Methods: The clinical data of 186 patients with NSCLC treated with radical surgery in Affiliated Hospital of Youjiang Medical University for Nationalities of Baise were retrospectively analyzed. Multivariate logistic regression was applied to analyze the risk factors of recurrence within 1 year after radical resection of NSCLC. The R language (R 4.0.3 software package) was used in constructing the nomogram model, and the predictive value of the model was evaluated. Results: The recurrence rate of 186 patients within 1 year after radical surgery was 29.57%. After multivariate logistic regression analysis, pathological stage, number of lymph node metastasis, chronic obstructive pulmonary disease (COPD), postoperative plasma D-dimer, and carcinoembryonic antigen were independent factors for recurrence within 1 year after radical resection of NSCLC (P < 0.05). Based on the above independent risk factors, a nomogram model was established, with the distinction of AUC = 0.891 (95% CI: 0.819-0.964) and sensitivity and specificity of 70.3% and 97.8%, respectively. The calibration curve was close to the ideal curve. External validation of the model showed AUC = 0.801 (95% CI: 0.674-0.928), and sensitivity and specificity were 66.7% and 84.2%, respectively. Conclusion: The recurrence of NSCLC within 1 year after radical surgery was related to a variety of factors, and the nomogram model constructed based on risk factors had good goodness of fit, calibration, consistency of prediction, and prediction efficiency.
ABSTRACT
Multiple myeloma (MM) is a lethal hematological malignancy characterized by abundant myeloid cells in the microenvironment that fuel tumor progression. But the mechanism by which myeloid cells support myeloma cells has not been fully explored. We aimed to examine their effect on bone marrow cells of MM patients by scRNA-seq transcriptome analysis and reveal a high-resolution gene profile of myeloma cells and myeloma-associated myeloid cells. Based on correlation analysis of integrated scRNA-seq and bulk RNA-seq datasets from patients, we confirmed that myeloid-derived S100A9 was involved in TNFSF13B-dependent myeloma cell proliferation and survival. In the animal experiments, S100A9 was found to be critical for MM cell proliferation and survival via TNFSF13B production by myeloid cells, neutrophils, and macrophages. In-vitro analysis of patient primary myeloma cells further demonstrated that enhanced TNFSF13B signaling triggered the canonical NF-κB pathway to boost tumor cell proliferation. All these results suggest that myeloid-derived S100A9 is required for TNFSF13B/TNFRSF13B-dependent cell-fate specification, which provides fresh insights into MM progression.
